BR112017004883A2 - ensaio de diagnóstico baseado em fragmento de rgma - Google Patents
ensaio de diagnóstico baseado em fragmento de rgmaInfo
- Publication number
- BR112017004883A2 BR112017004883A2 BR112017004883A BR112017004883A BR112017004883A2 BR 112017004883 A2 BR112017004883 A2 BR 112017004883A2 BR 112017004883 A BR112017004883 A BR 112017004883A BR 112017004883 A BR112017004883 A BR 112017004883A BR 112017004883 A2 BR112017004883 A2 BR 112017004883A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnostic assay
- based diagnostic
- rgma
- rgma fragment
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048745P | 2014-09-10 | 2014-09-10 | |
| PCT/EP2015/070603 WO2016038084A1 (en) | 2014-09-10 | 2015-09-09 | Rgma fragment based diagnostic assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017004883A2 true BR112017004883A2 (pt) | 2017-12-05 |
Family
ID=54064367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017004883A BR112017004883A2 (pt) | 2014-09-10 | 2015-09-09 | ensaio de diagnóstico baseado em fragmento de rgma |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160069907A1 (enExample) |
| EP (1) | EP3191847A1 (enExample) |
| JP (1) | JP6879905B2 (enExample) |
| CN (2) | CN107076757A (enExample) |
| AU (2) | AU2015314240A1 (enExample) |
| BR (1) | BR112017004883A2 (enExample) |
| CA (1) | CA2956814A1 (enExample) |
| MX (2) | MX385216B (enExample) |
| TW (2) | TW202119030A (enExample) |
| WO (1) | WO2016038084A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2632476A1 (en) * | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
| MX2012006560A (es) * | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| CN116942831A (zh) | 2018-07-19 | 2023-10-27 | 国立大学法人东京大学 | Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法 |
| CN118767130A (zh) * | 2020-01-15 | 2024-10-15 | 国立大学法人大阪大学 | 糖尿病性自主神经障碍的预防或治疗剂 |
| CN112402554B (zh) * | 2020-10-26 | 2022-03-01 | 中国中医科学院广安门医院 | 一种治疗脑白质病的中药组合物及其应用 |
| US12306192B2 (en) | 2021-02-08 | 2025-05-20 | Cedars-Sinai Medical Center | Method of detecting cognitive impairment |
| EP4374300A4 (en) * | 2021-07-23 | 2025-06-11 | Cedars-Sinai Medical Center | Methods and systems for the early detection of ocular and/or neurological conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000002053A2 (en) * | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| MX2012006560A (es) * | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| KR102284780B1 (ko) * | 2009-12-09 | 2021-08-02 | 미쓰비시 타나베 파마 코퍼레이션 | Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법 |
| EP3252072A3 (en) * | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012047706A2 (en) * | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| EP2723866B1 (en) * | 2011-06-22 | 2018-03-28 | Universite Laval | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
-
2015
- 2015-09-09 WO PCT/EP2015/070603 patent/WO2016038084A1/en not_active Ceased
- 2015-09-09 TW TW109124697A patent/TW202119030A/zh unknown
- 2015-09-09 BR BR112017004883A patent/BR112017004883A2/pt not_active IP Right Cessation
- 2015-09-09 EP EP15759819.4A patent/EP3191847A1/en not_active Withdrawn
- 2015-09-09 CN CN201580048412.5A patent/CN107076757A/zh active Pending
- 2015-09-09 TW TW104129821A patent/TW201617612A/zh unknown
- 2015-09-09 MX MX2017003063A patent/MX385216B/es unknown
- 2015-09-09 JP JP2017513509A patent/JP6879905B2/ja not_active Expired - Fee Related
- 2015-09-09 AU AU2015314240A patent/AU2015314240A1/en not_active Abandoned
- 2015-09-09 CN CN202110521844.0A patent/CN113267630A/zh active Pending
- 2015-09-09 CA CA2956814A patent/CA2956814A1/en not_active Abandoned
- 2015-09-10 US US14/850,185 patent/US20160069907A1/en not_active Abandoned
-
2017
- 2017-03-08 MX MX2021009528A patent/MX2021009528A/es unknown
-
2019
- 2019-09-04 US US16/560,632 patent/US20200241012A1/en not_active Abandoned
-
2021
- 2021-03-02 US US17/190,135 patent/US20220018855A1/en not_active Abandoned
-
2022
- 2022-01-12 AU AU2022200160A patent/AU2022200160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107076757A (zh) | 2017-08-18 |
| AU2022200160A1 (en) | 2022-02-10 |
| US20160069907A1 (en) | 2016-03-10 |
| EP3191847A1 (en) | 2017-07-19 |
| US20220018855A1 (en) | 2022-01-20 |
| WO2016038084A1 (en) | 2016-03-17 |
| TW202119030A (zh) | 2021-05-16 |
| CA2956814A1 (en) | 2016-03-17 |
| US20200241012A1 (en) | 2020-07-30 |
| AU2015314240A1 (en) | 2017-02-09 |
| CN113267630A (zh) | 2021-08-17 |
| MX2021009528A (es) | 2021-09-08 |
| JP6879905B2 (ja) | 2021-06-02 |
| JP2017526930A (ja) | 2017-09-14 |
| MX385216B (es) | 2025-03-14 |
| MX2017003063A (es) | 2017-06-14 |
| TW201617612A (zh) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017004883A2 (pt) | ensaio de diagnóstico baseado em fragmento de rgma | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| IL260400B (en) | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | |
| PL3482209T3 (pl) | Oznaczenie do wykrywania alfa-synukleiny i sposób diagnozowania alfa-synukleinopatii | |
| MX383494B (es) | Ácidos nucleicos libres de células para el análisis del microbioma humano y componentes del mismo. | |
| EP3362060A4 (en) | BIOMARKERS FOR DIABETES AND TREATMENT OF DIABETES-BASED ILLNESSES | |
| EP3430171A4 (en) | DETECTION AND TREATMENT OF ANTI-PD1 THERAPY RESISTANT METASTATIC MELANOMA | |
| EP2740489A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA | |
| EP3377042A4 (en) | MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES | |
| EP2532367A4 (en) | PHARMACEUTICAL AGENT FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| EP3364915A4 (en) | MEDICAL DEVICE FOR DETECTING AND / OR STIMULATING TISSUE | |
| EP3491465A4 (en) | BACKLIGHTING ARRANGEMENT AND DISPLAY DEVICE | |
| CL2014003110A1 (es) | Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano. | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| BR112016003665A2 (pt) | anticorpos e ensaios para detecção do receptor 1 de folato | |
| EP2851429A4 (en) | PROTEIN AND PROTEIN CONJUGATES FOR THE TREATMENT OF DIABETES AND APPLICATIONS THEREOF | |
| HUE045724T2 (hu) | GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére | |
| IL245936A0 (en) | Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers | |
| EP2753365A4 (en) | MEDICINE AND METHODS OF TREATING INFLAMMATORY SUDDEN AND DISEASES | |
| EP3347492A4 (en) | METHOD FOR HISTOLOGICAL DIAGNOSIS AND TREATMENT OF ILLNESSES | |
| EP3303402A4 (en) | ANTIBODIES TO GLYPICAN-3 AND ITS USE TO CANCER DIAGNOSIS AND TREATMENT | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer | |
| EP3374370A4 (en) | PROCESS FOR DETECTING AND TREATING PULMONARY HYPERTONIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2739 DE 04-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |